Cofactor-independent phosphoglycerate mutase from nematodes has limited druggability, as revealed by two high-throughput screens.
Cofactor-independent phosphoglycerate mutase from nematodes has limited druggability, as revealed by two high-throughput screens.
复制标题
DOI：
10.1371/journal.pntd.0002628
复制
发表时间：
2014
影响因子：
3.8
通讯作者：
Wang MW
中科院分区：
文献类型：
--
作者：
Crowther GJ;Booker ML;He M;Li T;Raverdy S;Novelli JF;He P;Dale NR;Fife AM;Barker RH Jr;Kramer ML;Van Voorhis WC;Carlow CK;Wang MW
Cofactor-independent phosphoglycerate mutase (iPGAM) is essential for the growth of C. elegans but is absent from humans, suggesting its potential as a drug target in parasitic nematodes such as Brugia malayi, a cause of lymphatic filariasis (LF). iPGAM's active site is small and hydrophilic, implying that it may not be druggable, but another binding site might permit allosteric inhibition. As a comprehensive assessment of iPGAM's druggability, high-throughput screening (HTS) was conducted at two different locations: ∼220,000 compounds were tested against the C. elegans iPGAM by Genzyme Corporation, and ∼160,000 compounds were screened against the B. malayi iPGAM at the National Center for Drug Screening in Shanghai. iPGAM's catalytic activity was coupled to downstream glycolytic enzymes, resulting in NADH consumption, as monitored by a decline in visible-light absorbance at 340 nm. This assay performed well in both screens (Z′-factor >0.50) and identified two novel inhibitors that may be useful as chemical probes. However, these compounds have very modest potency against the B. malayi iPGAM (IC50 >10 µM) and represent isolated singleton hits rather than members of a common scaffold. Thus, despite the other appealing properties of the nematode iPGAMs, their low druggability makes them challenging to pursue as drug targets. This study illustrates a “druggability paradox” of target-based drug discovery: proteins are generally unsuitable for resource-intensive HTS unless they are considered druggable, yet druggability is often difficult to predict in the absence of HTS data. Parasitic worms like Brugia malayi cause widespread lymphatic filariasis (LF) in southeast Asia and sub-Saharan Africa. The adult worms causing most of the symptoms of LF are difficult to treat with existing drugs. As a possible step toward new LF drugs, we searched for inhibitors of the B. malayi cofactor-independent phosphoglycerate mutase (iPGAM), an enzyme thought to be critical to survival and development of this parasite. Despite testing over 100,000 compounds at each of two screening centers, we found only two compounds that consistently inhibited the B. malayi enzyme more strongly than the cofactor-dependent enzyme found in humans. These compounds have limited potency and are not especially great starting points for drug development. The 3-dimensional structure of iPGAM suggests that the active site is difficult to access from the surrounding solvent, which may partly explain our very low yield of inhibitors. We conclude that iPGAM may not be an ideal drug target in B. malayi or related organisms because it is difficult to inhibit with druglike compounds.
登录
查看更多内容
影响因子：
3.7
作者：
Kumar A;Zhang M;Zhu L;Liao RP;Mutai C;Hafsat S;Sherman DR;Wang MW
通讯作者：
Wang MW
从小分子代谢的角度对药物空间的映射。
影响因子：
4.3
作者：
Adams JC;Keiser MJ;Basuino L;Chambers HF;Lee DS;Wiest OG;Babbitt PC
通讯作者：
Babbitt PC
影响因子：
64.5
作者：
Dessen, A;Tang, J;Somers, WS
通讯作者：
Somers, WS
影响因子：
5.8
作者：
Laurie, ATR;Jackson, RM
通讯作者：
Jackson, RM
影响因子：
3.4
作者：
Nukui, Masatoshi;Mello, Luciane V.;Jedrzejas, Mark J.
通讯作者：
Jedrzejas, Mark J.